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Background and Aims 24 
ESPEN guidelines advocate patients with inflammatory bowel disease (IBD) have their micronutrient 25 
levels checked regularly.  This study described the micronutrient status of patients with quiescent IBD 26 
and explore whether biochemical micronutrient deficiencies related to time to subsequent disease 27 
relapse.  28 
Methods 29 
Sixteen micronutrients were measured prospectively in blood of patients with IBD in clinical remission 30 
[Harvey Bradshaw Index (HBI) ≤4 in Crohn’s disease (CD) and a partial Mayo score <2 in ulcerative colitis 31 
(UC)]. Patients were followed prospectively using the electronic patient records.  The ability of 32 
micronutrient status to predict time to relapse was tested with survival analysis and Cox regression. 33 
Results 34 
Ninety-three patients were enrolled; Fifty (54%) were also in biochemical remission defined as a normal 35 
faecal calprotectin (<250µg/g), C-reactive protein (<10 mg/L) and serum albumin (>35 g/L). Deficiencies 36 
in vitamin D were identified in 27(29%), zinc in 15(16%), vitamin B6 in 13(14%), vitamin C in 12(13%) and 37 
vitamin B12 in 10(11%). Fewer participants had low serum folate 7(8%), ferritin 8(9%), copper 4(4%), 38 
magnesium 4(4%) and plasma selenium 3(3%). Zinc deficiency was predictive of a shorter time to 39 
subsequent relapse (HR: 6.9; 95%CI [1.9 to 26], p=0.008); in sub analysis of those with CD this effect was 40 




We identified biochemical deficiencies for several micronutrients among adults with IBD clinically in 43 
remission. We have also highlighted a significant association between zinc deficiency and time to 44 





Patients with inflammatory bowel disease (IBD) may be at risk of malnutrition[1].  The European Society 48 
of Clinical Nutrition and Metabolism (ESPEN) recommend regular screening for micronutrient 49 
deficiencies in this population[2]. This is rarely done in routine practice due to the limited availability of 50 
specialised laboratory facilities to undertake such analyses and the dearth of data to suggest that clinical 51 
presentations of micronutrient deficiencies are common, despite low biochemical levels often being 52 
reported[1]. The acute phase response perturbs plasma concentrations of certain vitamins and trace 53 
elements in active disease so it is often unclear the extent to which biochemical deficiencies reflect body 54 
store status or whether these are an epiphenomenon of the systemic inflammatory response (SIR)[3, 4]. 55 
In our tertiary referral unit, we introduced the ESPEN recommendations for micronutrient 56 
screening in clinical practice for patients with quiescent disease. Here, we present the prevalence of 57 
biochemical deficiencies for 16 micronutrients in adult patients with IBD with quiescent disease and 58 





Materials and Methods 62 
Study population 63 
We prospectively audited the micronutrient status of adult patients attending the Glasgow Royal 64 
Infirmary from September 2017 until July 2018.  Participants eligible were in clinical remission, [Harvey 65 
Bradshaw Index ≤4 in Crohn’s disease (CD) and a partial Mayo score <2 in ulcerative colitis (UC)]. Clinical 66 
data collected included Montreal classification of IBD phenotype and current medication. Plasma 67 
vitamin A, vitamin C, vitamin E/cholesterol ratio, vitamin D, vitamin K/triglyceride ratio, copper, 68 
selenium and zinc; serum folate, vitamin B12, ferritin and magnesium; whole blood vitamin B1 and 69 
manganese and erythrocyte selenium, vitamin B2 and vitamin B6 were analysed.  Serum albumin, C-70 
reactive protein (CRP) and faecal calprotectin (FC) were analysed. Patients were followed prospectively 71 
using their electronic patient records. No treatment modifications or supplementation were made based 72 
on abnormal micronutrient results in the absence of clinical symptoms during the study period. Time to 73 
relapse was defined as the need for escalation of IBD-related medication, hospitalization or surgery for 74 
IBD. As an audit of good clinical practice the requirement for ethics approval was waived[5]. 75 
 76 
Micronutrient analysis. 77 
Micronutrients were assayed at the Scottish Trace Element and Micronutrient Diagnostic and Research 78 
Laboratory, the national accredited service, as explained previously[6]. Plasma vitamin A (retinol) and E 79 
(α-tocopherol) were determined by high-performance liquid chromatography (HPLC). Plasma vitamin E 80 
was corrected for plasma total cholesterol to adjust for any variations in plasma lipids. Plasma Vitamin K 81 
(phylloquinone) was assessed using liquid chromatography tandem mass spectrometry and corrected 82 
for triglyceride levels.  Vitamin B1 (thiamin diphosphate) was measured in whole blood using HPLC with 83 
post-column ferricyanide derivatization and fluorometric detection. Vitamin B2 (flavin adenine 84 
dinucleotide) was measured in erythrocytes with isocratic HPLC with a reversed-phase C18 column and 85 
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fluorescence detection. Vitamin B6 (pyridoxyl phosphate) concentrations in red cells was measured by 86 
HPLC using precolumn semicarbazide derivatization and fluorescence detection. Vitamin B2 and B6 87 
concentrations in red cells were adjusted to haemoglobin. Vitamin C status was measured in plasma on 88 
a C18 reversed-phase analytical column (with electrochemical detection). Vitamin D status was assessed 89 
by measuring 25-hydroxy vitamin D by liquid chromatography-tandem mass spectrometry. Inductively 90 
coupled plasma mass spectrometry (Agilent Technologies, Cheadle, UK) was used to measure plasma 91 
zinc, copper, selenium, erythrocyte selenium, whole blood manganese using germanium and scandium 92 
as an internal standard. All methods were tested and calibrated against certified reference material.  93 
The between batch coefficient of variation of all methods described above was <10%. 94 
 95 
Statistical analysis 96 
 Relationships between micronutrient with CRP, serum albumin and FC were explored with Spearman 97 
rank correlations. Predictors of micronutrient status (i.e. normal or deficient) were tested with linear 98 
and logistic regression analysis. The predictors explored were CRP, serum albumin, age, disease type, 99 
Montreal disease phenotype and behavior, use of micronutrient supplements, disease duration, gender, 100 
BMI and recent weight loss. The ability of micronutrient deficiencies to predict time to subsequent 101 




Ninety-three patients were assessed [N=59 with CD, N=34 with UC/IBD unclassified (Table 1)]. Faecal 106 
calprotectin samples were returned by 75 patients (81%). There were 6 (6.5%) patients with serum 107 
albumin < 35 g/litre, 10 (11%) with CRP >10 mg/litre and 14 (15%) with FC >250µg/g of stool. Of those 108 
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with a raised FC, the majority had CD (11/14, 79%). Fifty (54%) patients had normal FC, CRP and serum 109 
albumin and were classified as in “biochemical” remission.  110 
 111 
Prevalence of biochemical deficiencies  112 
There were deficiencies of vitamin D in 27 (29%), zinc in 15 (17%), vitamin B6 in 13 (14%), vitamin C in 12 113 
(13%) and vitamin B12 in 10 (11%) patients. Seven (8%) patients had low serum folate, 8 (9%) low 114 
ferritin, 4 (4%) low copper, 4 (4%) low magnesium and 3 (3%) with low plasma selenium. For the 115 
remaining micronutrients (vitamin B1, vitamin B2, vitamin E, vitamin K, manganese and RBC selenium) 116 
biochemical deficiencies were uncommon (Figure 1). There were no significant differences in 117 
micronutrient status between patients with CD and UC (Figure 1). 118 
Among those in biochemical remission, vitamin D deficiency was identified in 16 people (32%), 119 
low vitamin B6 in 8 (16%), zinc in 7(14%), ferritin in 6 (12%), vitamin B12 in 5 (10%) and vitamin C in 5 120 
(10%). Four patients were deficient in folate (8%), 3 (6%) low in copper and 2 (4%) low in vitamin A.  121 
Deficiencies of plasma magnesium, selenium, vitamin E, vitamin B2 and vitamin K were seen for single 122 
patients. No deficiencies were noted with RBC selenium and Vitamin B1 (Figure 1). 123 
 124 
Correlations between micronutrients with albumin, CRP and FC 125 
Significant correlations were observed between albumin and vitamin B2 (rho = 0.24; p=0.018), vitamin A 126 
(rho = 0.20; p=0.061), vitamin C (rho = 0.20; p=0.054), plasma selenium (rho = 0.28; p=0.007), zinc (rho 127 
=0.28; p=0.007) and serum folate (rho=-0.33; p=0.002). Likewise, CRP levels were statistically 128 
significantly correlated with vitamin B2 (rho =0.20; p=0.054), plasma selenium (rho = -0.28; p=0.006), 129 
RBC selenium (rho = -0.25; p= 0.015), copper (rho =0.41; p<0.001) ferritin (rho = 0.27; p=0.010) and 130 
folate (rho = 0.25; p=0.019). FC levels correlated significantly with magnesium (rho= -0.26, p=0.044), 131 




Predictors of micronutrient deficiencies 134 
We explored possible predictors for the micronutrient deficiencies that were encountered in more than 135 
8% of patients (vitamins B6, B12, vitamin C, vitamin D, ferritin, zinc, folate) and for high copper levels. In 136 
patients with CD with a stricturing phenotype, deficiency of B6 was more common (p=0.001) than in 137 
patients with an inflammatory phenotype. Young age (p=0.031), low albumin (p=0.018) and low BMI 138 
(p<0.0001) were predictive of zinc deficiency and high CRP was predictive of high copper levels 139 
(p=0.001). Seven patients received folic acid supplementation, 4 received B12 and 2 iron; none of which 140 
was associated with micronutrient status. 141 
 142 
Micronutrient status and prediction of time to relapse 143 
There was no association between micronutrient status and the duration of remission prior to 144 
micronutrient assessment. In survival analysis, zinc deficiency was predictive of a shorter time to 145 
subsequent relapse (HR: 6.9; 95%CI [1.9 to 26], p=0.008) (Figure 2a). When sub-analysis was performed 146 
in the subset of patients with CD only (Figure 2b), this association became even more profound 147 
(p=0.001). Neither CRP nor FC levels were predictive of time to relapse and a non-significant association 148 
(p=0.059) was seen for low albumin levels.  The association between zinc deficiency and time to 149 
subsequent relapse remained statistically significant (HR: 9.5; 95%CI [2.2 to 42], p=0.0029) even after 150 
adjusting for plasma CRP (HR: 1; p=0.775) and FC (HR: 1; p=0.133). Subset analysis in patients in 151 
biochemical remission was not possible due to the very small numbers of patients with micronutrient 152 





Despite the absence of overt clinical manifestations of deficiencies, a few patients with quiescent IBD 156 
had low biochemical levels for vitamin D, vitamin B6, vitamin B12, vitamin C and zinc. We have also 157 
identified a strong relationship between biochemical zinc deficiency and time to next relapse, 158 
particularly in CD.  159 
We have previously demonstrated the marked effect SIR can have on circulating plasma 160 
micronutrient levels. This can affect almost all micronutrients measured in plasma including vitamin D 161 
by approximately 35%, zinc by 25% and vitamin C by 75%[3, 4, 7]. Despite this long-standing evidence, 162 
plasma micronutrient concentrations are often not interpreted in the context of raised markers of 163 
inflammation in clinical settings. Sikora and colleagues, assessed micronutrient levels in newly diagnosed 164 
paediatric patients, and they noted zinc deficiency but also low albumin, low haemoglobin and high 165 
erythrocyte sedimentation rate (ESR) indicating active inflammation[8]. We would suggest that these 166 
observations were reflective of active disease and an epiphenomenon rather than indicating true 167 
micronutrient deficiencies. This is in accordance with our observations that certain micronutrients 168 
correlated either negatively or positively with CRP and serum albumin; both established positive and 169 
negative acute phase reactants respectively. However, when we looked at the patients in biochemical 170 
remission only, several of these deficiencies persisted. These can be true deficiencies, or these findings 171 
may be explained by the fact that the inflammatory markers used here are insensitive marker of active 172 
disease and mucosal healing in IBD. 173 
This research adds to that of Siva et al, who looked at zinc deficiency and clinical outcomes in 174 
IBD[9]. They demonstrated that in patients with both UC and particularly in CD, those with low zinc 175 
concentrations also had a lower albumin and higher CRP.  When these variables were controlled for, zinc 176 
deficiency remained an independent predictor of a CD-related hospitalization, complication or operation 177 
compared to those with normal levels.  The significant relationship between zinc deficiency and time to 178 
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relapse in quiescent Crohn’s disease is interesting and may have implications for clinical practice either 179 
as a prognostic marker of disease relapse but also as potential therapeutic target. Although low levels of 180 
zinc are found among patients with IBD, clinical manifestations are much rarer. This might be because 181 
low zinc level is a sensitive marker for disease activity in patients with subclinically active mucosal 182 
disease. Alternatively, as zinc is essential for cell growth and intestinal epithelial homeostasis 183 
patients[10] with a deficiency are more likely to suffer worsening mucosal inflammation. In two 184 
prospective cohorts of women, intake of zinc was inversely associated with risk of CD but not UC[11] 185 
further corroborating on the observations of the current study. 186 
We did unexpectedly show that FC was not predictive of a relapse in patients with IBD despite 187 
ourselves[12] demonstrating this previously. However only 12 patients with CD had elevated FC at 188 
inclusion, and it is likely that this study lacked power to demonstrate this.   189 
The ESPEN guidelines[2] recommend that patients in clinical remission should have their 190 
micronutrients screened with a view to supplementation but remark that inflammation may affect these 191 
results.  We have shown that almost half of our cohort identified as clinically in remission were not in 192 
‘biochemical’ remission making the identification of such patients challenging. It is also unclear whether 193 
supplementation in the presence of active disease would improve body stores. Santucci et al found that 194 
37% of patients with zinc deficiency remained deficient and 15% had developed a new zinc deficiency 195 
despite supplementation[13]. 196 
In conclusion, we have identified several biochemical micronutrient deficiencies among an IBD 197 
cohort clinically and biochemically in remission. The potential for zinc levels to provide prognostic 198 
information in IBD course or comprise therapeutic target to maintain disease remission warrant further 199 
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Figure legends 218 
Figure 1: Prevalence of vitamin biochemical deficiencies among all patients, by IBD type and within 219 
those in biochemical remission   220 
 221 
Figure 2: Panel A: Survival analysis displaying time to relapse in those deficient in zinc compared to 222 
those with sufficient levels (all patients with IBD), Panel B: Survival analysis displaying time to relapse in 223 
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